WINT

WINT

USD

Windtree Therapeutics Inc. Common Stock

$0.618-0.031 (-4.780%)

Echtzeitkurs

Healthcare
Biotechnologie
Vereinigte Staaten

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen
Unternehmensfundamentaldaten
Handelsstatistiken

Marktkennzahlen

Eröffnung

$0.648

Hoch

$0.650

Tief

$0.600

Volumen

1.29M

Unternehmensfundamentaldaten

Marktkapitalisierung

2.3M

Branche

Biotechnologie

Land

United States

Handelsstatistiken

Durchschnittliches Volumen

4.53M

Börse

NCM

Währung

USD

52-Wochen-Spanne

Tief $0.52Aktuell $0.618Hoch $737.5

Ähnliche Nachrichten

GlobeNewswire

Windtree Receives Offer for Its Preclinical Oncology Drug Candidate

Company to receive $7.0 million up front for its preclinical oncology drug candidate Up to $130.0 million in milestone payments starting with initiation of Phase 1 High single digit royalties that could total up to

Mehr anzeigen
Windtree Receives Offer for Its Preclinical Oncology Drug Candidate
BusinessWire

Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors

Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the appointment of Saundra Pelletier, CEO of Evofem Biosciences, Inc.

Mehr anzeigen
Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors
GlobeNewswire

Windtree Announces Plan for Cryptocurrency Treasury Policy

WARRINGTON, Pa., June 03, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company and advancing

Mehr anzeigen
Windtree Announces Plan for Cryptocurrency Treasury Policy
GlobeNewswire

Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025

Istaroxime has previously completed two positive Phase 2 studies in SCAI Stage B cardiogenic shock; the SEISMiC C study in SCAI Stage C cardiogenic shock is another step progressing to the istaroxime cardiogenic shock

Mehr anzeigen
Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025